

Special Issue

Advances in Drug Treatments on Immunomodulatory and Neuroprotective Targets in Multiple Sclerosis

Message from the Guest Editors

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease mainly affecting the Central Nervous System. Advances in comprehending this pathology involve understanding the complex interactions between the different systems, not only nervous and immune (IS) but also the endocrine and metabolic, also with the various tissues and organs involved, as well as considering their response to treatments. There is currently no cure for MS, and treatment is mainly based on Disease-Modifying Therapies that act on the IS to decrease the relapse rate and the progression of brain lesions, thus limiting neurological deterioration. Identifying subgroups of patients with MS is crucial to understanding the disease's evolution and the response to treatment since subgroups of patients share some characteristics that define variations in the drug effect, diversity of molecular targets, and differences in response to treatment. For these reasons, it is essential to understand the molecular processes further causing MS heterogeneity and varying therapeutic responses, concentrating on immunomodulatory and neuroprotective targets, to advance clinical treatments and better understand the illness.

Guest Editors

Dr. Daniel Ortuño-Sahagún

Instituto de Investigación en Ciencias Biomédicas (IICB), Centro Universitario de Ciencias de las Salud (CUCS), Universidad de Guadalajara, Guadalajara, Mexico

Dr. Lenin Pavón

Laboratorio de Psicoimmunología, Dirección de Investigaciones en Neurociencias Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México 14370, Mexico

Deadline for manuscript submissions

closed (15 February 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/134392

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)